Developer docs
API playgroundTry for free, no card

Search company profiles

Anumana

Full company profile

uuid0000ajc

Namestring
Anumana
Legal namestring
Anumana, Inc.
Websiteurl
anumana.ai
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI ECG analysis, cardiovascular diagnostics software, heart failure detection, electrocardiogram algorithms, cardiac AI platform
Industry4 codes
PRIMARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
AI-Enabled Cardiac Diagnostics Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Medicare Reimbursement for ECG-AI LEF
TypeSubscription Recurring
Description

The company's ECG-AI LEF algorithm received Medicare reimbursement as of January 2025 under the CMS Hospital Outpatient Prospective Payment System (OPPS) final rule, assigned to APC 5734. Category III CPT codes (0764T and 0765T) were assigned in 2023. This provides recurring revenue from outpatient settings for detecting low ejection fraction in adults at risk for heart failure.

anumana.ai
2Pharmaceutical Partnership - Novartis
TypeLicensing Royalties
Description

Multi-year strategic collaboration with Novartis Pharmaceuticals Corporation to deploy a series of AI-powered software solutions for detecting heart disease. Anumana develops algorithms while Novartis provides funding and potential co-development resources.

anumana.ai
3Pharmaceutical Partnership - Pfizer
TypeLicensing Royalties
Description

Multi-year agreement with Pfizer for Anumana to develop an investigational AI electrocardiogram algorithm to help identify patients who may be at risk of cardiac amyloidosis. Pfizer-backed development with potential for future licensing revenue.

anumana.ai
4Philips ECG AI Marketplace Distribution
TypeSubscription Recurring
Description

Partnership with Royal Philips as inaugural partner on the ECG AI Marketplace platform. Provides distribution channel to U.S. healthcare systems through Philips' established customer base, potentially generating revenue through algorithm usage fees or licensing arrangements.

hlth.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1ECG-AI
Description

AI-powered electrocardiogram analysis technology platform that detects cardiovascular disease from standard 12-lead ECGs

anumana.ai
+3 more records
Core offering1 text field

Anumana develops and commercializes FDA-cleared AI-powered ECG analysis software (ECG-AI Platform) that detects cardiovascular conditions from standard 12-lead electrocardiograms. The portfolio includes algorithms for low ejection fraction, pulmonary hypertension, and cardiac amyloidosis, with additional algorithms in development for hyperkalemia, aortic stenosis, atrial fibrillation, and hypertrophic cardiomyopathy. The software integrates directly into hospital EHR and ECG management systems and is sold to healthcare providers, health systems, and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • ECG-AI increased heart failure detection diagnosis rates by about a third (EAGLE trial, Nature Medicine)
+6 more records
Product overview1 text field

Anumana is an AI-driven health technology company offering a portfolio of FDA-cleared ECG-AI software solutions organized around its core ECG-AI Platform. The flagship product is the ECG-AI LEF algorithm for detecting low ejection fraction (heart failure risk), which received the company's first full FDA 510(k) clearance in October 2023 and became the first AI-enabled ECG technology to receive Medicare reimbursement in January 2025. The company has since expanded its portfolio with additional FDA-cleared algorithms including ECG-AI Pulmonary Hypertension (March 2026) and ECG-AI Cardiac Amyloidosis (April 2026). The platform processes standard 12-lead ECGs using deep learning neural networks to identify subtle cardiac disease signals invisible to the human eye, with results integrated directly into healthcare institutions' EHR workflows. Anumana's technology is built on data from over 22 million patient records spanning more than 20 years and is supported by more than 100 peer-reviewed publications. The company also holds more than 300 patents protecting its AI innovations.

Product and service5 records
1ECG-AI LEF (Low Ejection Fraction)
CategoryFDA-cleared diagnostic AI software (SaMD)
Description

FDA 510(k)-cleared AI algorithm that analyzes standard 12-lead ECGs to identify patients with reduced left ventricular ejection fraction (LEF), a key indicator of heart failure. Developed using approximately 2.9 million ECG-echo pairs from 676,000+ patients across diverse populations. The first AI-enabled ECG technology to receive Medicare reimbursement (January 2025).

2ECG-AI Pulmonary Hypertension
CategoryFDA-cleared diagnostic AI software (SaMD)
Description

FDA 510(k)-cleared AI algorithm designed to identify early signs of pulmonary hypertension (PH) using standard 12-lead ECGs. Developed using over 250,000 Mayo Clinic patient records, demonstrating 73% sensitivity and 74.4% specificity in a multi-center study of 21,066 patients across five U.S. health systems.

3ECG-AI Cardiac Amyloidosis
CategoryFDA-cleared diagnostic AI software (SaMD)
Description

First and only FDA-cleared AI algorithm for detecting cardiac amyloidosis using a standard 12-lead ECG. Identifies hidden cardiovascular disease from routine electrocardiograms, enabling earlier detection of AL or ATTR cardiac amyloidosis with AUC of 0.92.

4NeuTrace EP Data Biome Platform
CategoryElectrophysiology data integration platform
Description

Proprietary, device-agnostic platform for holistic in-procedure data integration and real-time AI applications in cardiac electrophysiology. Covered by more than 35 pending and registered patents. Integrates patient EMR with ECG and EGM signals for improved EP procedure accuracy and safety.

5ECG-AI Hyperkalemia
CategoryPipeline diagnostic AI software (SaMD)
Description

AI algorithm in development for non-invasive detection of elevated blood potassium (hyperkalemia) from ECG signals. Received FDA Breakthrough Device Designation. Targets bloodless potassium monitoring in patients with chronic kidney disease.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Royal Philips
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-18
Description

Anumana is the inaugural partner on Royal Philips ECG AI Marketplace, a centralized platform that consolidates AI-powered cardiac diagnostic tools for U.S. healthcare systems. Anumana's FDA-cleared ECG-AI LEF algorithm is the first solution available on the marketplace, enabling hospitals to integrate AI algorithms into their workflows.

hlth.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-04-24
Description

Boston Scientific provided support for Anumana's expansion of its diagnostic ECG-AI technology into perioperative and acute cardiac care settings. Collaboration focused on bringing AI capabilities into additional clinical care pathways.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Partnership announced January 2025 for broader cardiac disease AI development. Collaboration aimed at expanding AI-enabled ECG analysis capabilities and market reach for cardiovascular disease detection applications.

4Accelerating Medicines Partnership Heart Failure (AMP HF) Program
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-24
Description

Anumana joined the NIH/NHLBI AMP Heart Failure Program providing access to real-world data to refine AI algorithms for earlier detection of complex heart conditions. Partnership enables use of BioData Catalyst platform and longitudinal cohort data for algorithm validation.

anumana.ai
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-20
Description

Multi-year agreement with Pfizer for development of investigational AI electrocardiogram algorithm to help identify patients at risk of cardiac amyloidosis. Pfizer provides funding and clinical development expertise while Anumana contributes AI technology development capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-13
Description

Multi-year strategic collaboration with Novartis Pharmaceuticals Corporation to deploy a series of AI-powered software solutions for detecting heart disease. Anumana develops and provides AI-ECG algorithms while Novartis contributes to development funding and potential commercialization support for cardiovascular AI applications.

Strategic tierSupportingTypeOthers
Description

National Heart, Lung, and Blood Institute sponsored longitudinal cohort study. Anumana accessed cohort data through HeartShare/AMP HF Program for validation of ECG-AI algorithms in heart failure prediction studies.

8Multi-Ethnic Study of Atherosclerosis (MESA)
Strategic tierSupportingTypeOthers
Description

NHLBI-sponsored multi-center longitudinal study of subclinical cardiovascular disease. Contributed data for multi-cohort validation of ECG-AI algorithms through HeartShare/AMP HF Program.

anumana.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mayo Clinic is the co-founding partner of Anumana and primary source of clinical data for algorithm development. Mayo Clinic Platform provides access to de-identified patient records spanning over 22 million records and 20 years of data. Mayo Clinic physicians serve as advisors and investigators for clinical validation studies.

10nference
Strategic tierCoreTypeStrategic or Co-development Partner
Description

nference is the co-founding partner of Anumana along with Mayo Clinic. nference provides its nSights real-world evidence generation platform and AI/ML technical capabilities. nference acquired rights to NeuTrace Data Biome platform for uses outside of cardiovascular field as part of the NeuTrace acquisition.

anumana.ai
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eko Health builds AI-enabled cardiac auscultation and ECG analysis tools for clinicians and health systems. Eko's AI cardiac detection platform overlaps directly with Anumana's ECG-AI franchise in applying deep learning to cardiac signal interpretation within hospital workflows.

TypeDirect peer
Description

AliveCor (KardiaMobile, KardiaStation) is an AI-ECG platform with FDA-cleared personal and clinical ECG devices. Anumana is a known collaboration partner of AliveCor (Jan 2025) and both companies operate AI-ECG algorithms for cardiovascular detection, although AliveCor is more consumer-proximate and Anumana is more hospital-anchored.

TypeDirect peer
Description

Ultromics develops AI-ECG and AI-echocardiography algorithms for cardiovascular disease detection, including heart failure with preserved ejection fraction (HFpEF). Anumana and Ultromics both apply deep learning to cardiac signals for early-disease detection, serving similar healthcare-system and pharma customers with FDA-cleared SaMD.

TypeBroad incumbent
Description

HeartFlow provides AI-enabled cardiac CT-FFR analysis for coronary disease. Although HeartFlow focuses on imaging rather than ECG, both companies sit in the AI-driven cardiovascular diagnostics category serving hospital systems and operating under similar CPT/reimbursement frameworks.

5Caption Health
TypeEmerging player
Description

Caption Health develops AI guidance for cardiac ultrasound (echocardiography). It overlaps with Anumana at the intersection of AI-driven cardiac diagnostics and clinician workflow, though focused on imaging rather than ECG signal analysis.

6Cardio Diagnostics
TypeDirect peer
Description

Cardio Diagnostics develops AI-driven epigenomic and ECG-based cardiovascular diagnostics. Its focus on AI-ECG for cardiovascular disease screening and risk stratification parallels Anumana's ECG-AI product line.

TypeEmerging player
Description

Cleerly applies AI to cardiac CT angiography for plaque analysis. Like Anumana, it offers AI diagnostic tools to healthcare systems for early cardiovascular disease detection, addressing a similar need but via imaging rather than ECG.

TypeBroad incumbent
Description

iRhythm Technologies (Zio long-term cardiac monitoring patch) is a publicly traded cardiac monitoring company. It overlaps with Anumana in AI-enabled arrhythmia and cardiovascular disease detection but focuses on ambulatory patch monitoring rather than 12-lead ECG analysis.

TypeBroad incumbent
Description

Royal Philips is both a strategic partner (Anumana is inaugural partner on the Philips ECG AI Marketplace) and a broad incumbent in cardiology informatics (ECG management systems, cardiac imaging, AI). The relationship signals both an opportunity and a competitive exposure for Anumana.

TypeBroad incumbent
Description

GE HealthCare is a major incumbent in cardiac diagnostics (ECG, imaging, monitoring) and is investing in AI cardiology. As a broad medtech incumbent with established hospital relationships, it represents both a competitive threat and a potential exit partner for Anumana.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anumana

AI-Enabled Cardiac Diagnostics Softwareanumana.ai

Anumana firmographics

Firmographics
Name
Anumana
Legal name
Anumana, Inc.
Website
https://anumana.ai
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Anumana industry classification

Industry
Product category
AI-Enabled Cardiac Diagnostics Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)

Keywords

  • AI ECG analysis
  • Cardiovascular diagnostics software
  • Heart failure detection
  • Electrocardiogram algorithms
  • Cardiac AI platform

Where Anumana is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Anumana business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medicare Reimbursement for ECG-AI LEF: The company's ECG-AI LEF algorithm received Medicare reimbursement as of January 2025 under the CMS Hospital Outpatient Prospective Payment System (OPPS) final rule, assigned to APC 5734. Category III CPT codes (0764T and 0765T) were assigned in 2023. This provides recurring revenue from outpatient settings for detecting low ejection fraction in adults at risk for heart failure.
  2. Pharmaceutical Partnership - Novartis: Multi-year strategic collaboration with Novartis Pharmaceuticals Corporation to deploy a series of AI-powered software solutions for detecting heart disease. Anumana develops algorithms while Novartis provides funding and potential co-development resources.
  3. Pharmaceutical Partnership - Pfizer: Multi-year agreement with Pfizer for Anumana to develop an investigational AI electrocardiogram algorithm to help identify patients who may be at risk of cardiac amyloidosis. Pfizer-backed development with potential for future licensing revenue.
  4. Philips ECG AI Marketplace Distribution: Partnership with Royal Philips as inaugural partner on the ECG AI Marketplace platform. Provides distribution channel to U.S. healthcare systems through Philips' established customer base, potentially generating revenue through algorithm usage fees or licensing arrangements.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Anumana product offering

Product offering

Core offering

Anumana develops and commercializes FDA-cleared AI-powered ECG analysis software (ECG-AI Platform) that detects cardiovascular conditions from standard 12-lead electrocardiograms. The portfolio includes algorithms for low ejection fraction, pulmonary hypertension, and cardiac amyloidosis, with additional algorithms in development for hyperkalemia, aortic stenosis, atrial fibrillation, and hypertrophic cardiomyopathy. The software integrates directly into hospital EHR and ECG management systems and is sold to healthcare providers, health systems, and pharmaceutical companies.

Product overview

Anumana is an AI-driven health technology company offering a portfolio of FDA-cleared ECG-AI software solutions organized around its core ECG-AI Platform. The flagship product is the ECG-AI LEF algorithm for detecting low ejection fraction (heart failure risk), which received the company's first full FDA 510(k) clearance in October 2023 and became the first AI-enabled ECG technology to receive Medicare reimbursement in January 2025. The company has since expanded its portfolio with additional FDA-cleared algorithms including ECG-AI Pulmonary Hypertension (March 2026) and ECG-AI Cardiac Amyloidosis (April 2026). The platform processes standard 12-lead ECGs using deep learning neural networks to identify subtle cardiac disease signals invisible to the human eye, with results integrated directly into healthcare institutions' EHR workflows. Anumana's technology is built on data from over 22 million patient records spanning more than 20 years and is supported by more than 100 peer-reviewed publications. The company also holds more than 300 patents protecting its AI innovations.

Differentiator

Problem solved

Functional benefit

Brands

  • ECG-AI: AI-powered electrocardiogram analysis technology platform that detects cardiovascular disease from standard 12-lead ECGs
  • ECG-AI LEF
  • ECG-AI Pulmonary Hypertension
  • ECG-AI Cardiac Amyloidosis

Products and services

  • ECG-AI LEF (Low Ejection Fraction) FDA 510(k)-cleared AI algorithm that analyzes standard 12-lead ECGs to identify patients with reduced left ventricular ejection fraction (LEF), a key indicator of heart failure. Developed using approximately 2.9 million ECG-echo pairs from 676,000+ patients across diverse populations. The first AI-enabled ECG technology to receive Medicare reimbursement (January 2025).
  • ECG-AI Pulmonary Hypertension FDA 510(k)-cleared AI algorithm designed to identify early signs of pulmonary hypertension (PH) using standard 12-lead ECGs. Developed using over 250,000 Mayo Clinic patient records, demonstrating 73% sensitivity and 74.4% specificity in a multi-center study of 21,066 patients across five U.S. health systems.
  • ECG-AI Cardiac Amyloidosis First and only FDA-cleared AI algorithm for detecting cardiac amyloidosis using a standard 12-lead ECG. Identifies hidden cardiovascular disease from routine electrocardiograms, enabling earlier detection of AL or ATTR cardiac amyloidosis with AUC of 0.92.
  • NeuTrace EP Data Biome Platform Proprietary, device-agnostic platform for holistic in-procedure data integration and real-time AI applications in cardiac electrophysiology. Covered by more than 35 pending and registered patents. Integrates patient EMR with ECG and EGM signals for improved EP procedure accuracy and safety.
  • ECG-AI Hyperkalemia AI algorithm in development for non-invasive detection of elevated blood potassium (hyperkalemia) from ECG signals. Received FDA Breakthrough Device Designation. Targets bloodless potassium monitoring in patients with chronic kidney disease.

Quantifiable outcome

  • ECG-AI increased heart failure detection diagnosis rates by about a third (EAGLE trial, Nature Medicine)
  • +6 more outcomes

Companies that use Anumana

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Anumana technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature7 records

Anumana partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and supporting.

  • Royal PhilipscoreTechnology or Integration · 18 July 2025Anumana is the inaugural partner on Royal Philips ECG AI Marketplace, a centralized platform that consolidates AI-powered cardiac diagnostic tools for U.S. healthcare systems. Anumana's FDA-cleared ECG-AI LEF algorithm is the first solution available on the marketplace, enabling hospitals to integrate AI algorithms into their workflows.
  • Boston ScientificsupportingStrategic or Co-development Partner · 24 April 2025Boston Scientific provided support for Anumana's expansion of its diagnostic ECG-AI technology into perioperative and acute cardiac care settings. Collaboration focused on bringing AI capabilities into additional clinical care pathways.
  • AliveCorsupportingTechnology or Integration · 1 January 2025Partnership announced January 2025 for broader cardiac disease AI development. Collaboration aimed at expanding AI-enabled ECG analysis capabilities and market reach for cardiovascular disease detection applications.
  • Accelerating Medicines Partnership Heart Failure (AMP HF) ProgramcoreStrategic or Co-development Partner · 24 October 2024Anumana joined the NIH/NHLBI AMP Heart Failure Program providing access to real-world data to refine AI algorithms for earlier detection of complex heart conditions. Partnership enables use of BioData Catalyst platform and longitudinal cohort data for algorithm validation.
  • PfizercoreStrategic or Co-development Partner · 20 December 2022Multi-year agreement with Pfizer for development of investigational AI electrocardiogram algorithm to help identify patients at risk of cardiac amyloidosis. Pfizer provides funding and clinical development expertise while Anumana contributes AI technology development capabilities.
  • NovartiscoreStrategic or Co-development Partner · 13 July 2022Multi-year strategic collaboration with Novartis Pharmaceuticals Corporation to deploy a series of AI-powered software solutions for detecting heart disease. Anumana develops and provides AI-ECG algorithms while Novartis contributes to development funding and potential commercialization support for cardiovascular AI applications.
  • Framingham Heart StudysupportingOthersNational Heart, Lung, and Blood Institute sponsored longitudinal cohort study. Anumana accessed cohort data through HeartShare/AMP HF Program for validation of ECG-AI algorithms in heart failure prediction studies.
  • Multi-Ethnic Study of Atherosclerosis (MESA)supportingOthersNHLBI-sponsored multi-center longitudinal study of subclinical cardiovascular disease. Contributed data for multi-cohort validation of ECG-AI algorithms through HeartShare/AMP HF Program.
  • Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic is the co-founding partner of Anumana and primary source of clinical data for algorithm development. Mayo Clinic Platform provides access to de-identified patient records spanning over 22 million records and 20 years of data. Mayo Clinic physicians serve as advisors and investigators for clinical validation studies.
  • nferencecoreStrategic or Co-development Partnernference is the co-founding partner of Anumana along with Mayo Clinic. nference provides its nSights real-world evidence generation platform and AI/ML technical capabilities. nference acquired rights to NeuTrace Data Biome platform for uses outside of cardiovascular field as part of the NeuTrace acquisition.

Scale indicators13 records

Recent moves8 records

Expansion highlights7 records

Anumana competitors and assessment

Company assessment

Direct peers

  • Eko Health: Eko Health builds AI-enabled cardiac auscultation and ECG analysis tools for clinicians and health systems. Eko's AI cardiac detection platform overlaps directly with Anumana's ECG-AI franchise in applying deep learning to cardiac signal interpretation within hospital workflows.
  • AliveCor: AliveCor (KardiaMobile, KardiaStation) is an AI-ECG platform with FDA-cleared personal and clinical ECG devices. Anumana is a known collaboration partner of AliveCor (Jan 2025) and both companies operate AI-ECG algorithms for cardiovascular detection, although AliveCor is more consumer-proximate and Anumana is more hospital-anchored.
  • Ultromics: Ultromics develops AI-ECG and AI-echocardiography algorithms for cardiovascular disease detection, including heart failure with preserved ejection fraction (HFpEF). Anumana and Ultromics both apply deep learning to cardiac signals for early-disease detection, serving similar healthcare-system and pharma customers with FDA-cleared SaMD.
  • Cardio Diagnostics: Cardio Diagnostics develops AI-driven epigenomic and ECG-based cardiovascular diagnostics. Its focus on AI-ECG for cardiovascular disease screening and risk stratification parallels Anumana's ECG-AI product line.

Broad incumbents

  • HeartFlow: HeartFlow provides AI-enabled cardiac CT-FFR analysis for coronary disease. Although HeartFlow focuses on imaging rather than ECG, both companies sit in the AI-driven cardiovascular diagnostics category serving hospital systems and operating under similar CPT/reimbursement frameworks.
  • iRhythm Technologies: iRhythm Technologies (Zio long-term cardiac monitoring patch) is a publicly traded cardiac monitoring company. It overlaps with Anumana in AI-enabled arrhythmia and cardiovascular disease detection but focuses on ambulatory patch monitoring rather than 12-lead ECG analysis.
  • Philips (Royal Philips): Royal Philips is both a strategic partner (Anumana is inaugural partner on the Philips ECG AI Marketplace) and a broad incumbent in cardiology informatics (ECG management systems, cardiac imaging, AI). The relationship signals both an opportunity and a competitive exposure for Anumana.
  • GE HealthCare: GE HealthCare is a major incumbent in cardiac diagnostics (ECG, imaging, monitoring) and is investing in AI cardiology. As a broad medtech incumbent with established hospital relationships, it represents both a competitive threat and a potential exit partner for Anumana.

Emerging players

  • Caption Health: Caption Health develops AI guidance for cardiac ultrasound (echocardiography). It overlaps with Anumana at the intersection of AI-driven cardiac diagnostics and clinician workflow, though focused on imaging rather than ECG signal analysis.
  • Cleerly: Cleerly applies AI to cardiac CT angiography for plaque analysis. Like Anumana, it offers AI diagnostic tools to healthcare systems for early cardiovascular disease detection, addressing a similar need but via imaging rather than ECG.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Anumana social profiles

Digital presence

Anumana compliance and trust

Trust signal

Compliance6 records

Anumana financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anumana leadership team

Management profile

Number of profiles

Profiles8 records

Anumana subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Anumana funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anumana M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anumana

What does Anumana do?

Anumana develops and commercializes FDA-cleared AI-powered ECG analysis software (ECG-AI Platform) that detects cardiovascular conditions from standard 12-lead electrocardiograms. The portfolio includes algorithms for low ejection fraction, pulmonary hypertension, and cardiac amyloidosis, with additional algorithms in development for hyperkalemia, aortic stenosis, atrial fibrillation, and hypertrophic cardiomyopathy. The software integrates directly into hospital EHR and ECG management systems and is sold to healthcare providers, health systems, and pharmaceutical companies.

Is Anumana a public or private company?

Anumana is a private company. It is classified as venture growth investor backed and is currently operating.

When was Anumana founded?

Anumana was founded in 2021. It employs 101 to 250 people.

Where is Anumana based?

Anumana is headquartered in Cambridge, United States, in the North America region.

How does Anumana make money?

Four revenue lines are on record. Medicare Reimbursement for ECG-AI LEF is the primary driver. The others are pharmaceutical Partnership - Novartis, pharmaceutical Partnership - Pfizer and philips ECG AI Marketplace Distribution.

Who are Anumana's main competitors?

Direct peers on record are Eko Health, AliveCor, Ultromics and Cardio Diagnostics. Broad incumbents are HeartFlow, iRhythm Technologies, Philips (Royal Philips) and GE HealthCare. Emerging players are Caption Health and Cleerly.

Does Anumana have an API?

No public API is recorded for Anumana.

What industry is Anumana in?

Anumana's product category is AI-Enabled Cardiac Diagnostics Software. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity), with a secondary code of HLALAGAB, Cardiology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesAI-ECG: A New Market For A Century-Old TestAI-ECG algorithms are rapidly gaining FDA clearance and hospital deployment despite clinical skepticism over evidence standards, with companies Anumana, Viz.ai, and AliveCor clearing regulatory hurdles for screening conditions like low ejection fraction, pulmonary hypertension, and cardiac amyloidosis on routine ECG tracings. Viz.ai reports diagnosis time for hypertrophic cardiomyopathy dropping from five years to five weeks at hundreds of US sites, while Medicare added reimbursement codes for AI-enabled ECG analysis in 2025. The core disagreement centers on whether evidence standards have been met for guideline adoption, with some clinicians requiring large RCTs demonstrating mortality benefit before accepting AI reads in clinical care.Mpo-magFDA Clears ECG-AI Algorithm for Early Detection of Pulmonary HypertensionAnumana received FDA 510(k) clearance for its pulmonary hypertension algorithm, the first such AI tool cleared for standard 12-lead ECGs. The algorithm detected PH with 73% sensitivity and 74.4% specificity in a study of 21,066 patients, and identified over 85% of PAH cases. It integrates with EHR systems and is available for reimbursement.Business Wire BlogAnumana Named to Fast Company’s 2026 Most Innovative Companies AwardsAnumana, an AI-driven cardiovascular detection company, has been named to Fast Company's 2026 Most Innovative Companies list in the Medical Devices category for its development of AI-enabled ECG detection algorithms that identify hidden cardiovascular disease from routine electrocardiograms. The company has advanced a portfolio of FDA-cleared ECG-AI software solutions, with its ECG-AI LEF algorithm becoming the first approved Medicare reimbursement for an AI-enabled ECG technology detecting heart failure risk as of January 2025. Anumana, co-founded by nference and Mayo Clinic, has published over 100 peer-reviewed studies and holds more than 300 patents supporting its AI innovations.Medical Device NetworkFDA approves Anumana’s pulmonary hypertension algorithmThe FDA granted 510(k) clearance to Anumana for its ECG-AI pulmonary hypertension detection algorithm, a software-as-a-medical-device designed to identify early signs of PH using standard 12-lead ECGs. The algorithm integrates with electronic health record systems and was developed using data from over 250,000 Mayo Clinic patient records, demonstrating 73% sensitivity and 74.4% specificity in a validation study of 21,066 patients across five US health systems. Anumana, co-founded by Mayo Clinic, partnered with AliveCor in January 2025 for broader cardiac disease AI development.AijournAnumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary HypertensionAnumana, a cardiovascular AI company co-founded by nference and Mayo Clinic, has received FDA 510(k) clearance for its pulmonary hypertension (PH) algorithm, making it the first PH algorithm cleared for use with standard 12-lead electrocardiograms. The algorithm, developed using over 250,000 de-identified patient records from Mayo Clinic, demonstrated 73% sensitivity and 74.4% specificity in a multi-center study of 21,066 patients across five U.S. health systems. The clearance enables broader deployment of the AI-enabled diagnostic tool across care settings, with potential to detect PH earlier in patients who often face diagnostic delays exceeding two years.MorningstarAnumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary HypertensionAnumana, a cardiovascular AI company co-founded by nference and Mayo Clinic, has received U.S. FDA 510(k) clearance for its pulmonary hypertension (PH) algorithm, the first such AI-enabled SaMD cleared for use with standard 12-lead electrocardiograms. The algorithm, developed using over 250,000 de-identified patient records from Mayo Clinic, demonstrated 73% sensitivity and 74.4% specificity in detecting PH in an independent multi-center study of 21,066 patients across five U.S. health systems. The clearance enables broader clinical accessibility across care settings, integrating with existing EHR systems and workflows to support earlier detection of the progressive, life-threatening condition estimated to affect up to 1% of the global population.PharmiWeb.comAnumana Named to Fast Company’s 2026 Most Innovative Companies AwardsAnumana, an AI-driven health technology company specializing in cardiovascular detection algorithms, has been named to Fast Company's 2026 Most Innovative Companies list in the Medical Devices category. The recognition highlights the company's development of FDA-cleared ECG-AI algorithms that detect early signs of cardiovascular disease from routine electrocardiograms, including the ECG-AI LEF algorithm which received Medicare reimbursement in January 2025 as the first approved payment for an AI-enabled ECG technology for heart failure risk. Anumana, co-founded by nference and Mayo Clinic, has published over 100 peer-reviewed studies and holds more than 300 patents, with continued expansion into structural heart disease, interventional cardiology, and electrophysiology.Business Wire BlogAnumana Advances AI-Driven Cardiovascular Science with Late-Breaking Heart Failure Study and Multiple Abstracts at AHA 2025Anumana announced new clinical data at the AHA 2025 Scientific Sessions, demonstrating that its ECG-AI technology significantly enhances the prediction of incident heart failure compared to standard clinical risk models. The study, involving over 14,000 participants, showed that integrating Anumana's AI with existing risk equations reclassified a significant portion of individuals into higher-risk categories, potentially allowing for earlier preventive therapy.InsideprecisionmedicineCharting a Path to the Right Diagnosis with AI CopilotsHealthcare institutions are increasingly deploying AI tools—particularly large language models—to assist clinicians with diagnostic tasks, including differential diagnosis, radiology interpretation, and cardiology analysis. Companies like Qure.ai, Anumana, and Caris Life Sciences have developed FDA-cleared AI models that analyze imaging, electrocardiograms, and electronic health records to improve accuracy and speed of diagnosis. Experts emphasize that successful implementation requires seamless integration into clinical workflows, rigorous local validation, and addressing concerns around data quality and accountability, while warning that poor integration can undermine even well-designed tools.HLTHPhilips and Anumana Partner to Launch ECG AI Marketplace for Enhanced Cardiac DiagnosticsPhilips has launched an ECG AI Marketplace, a centralized platform that consolidates AI-powered cardiac diagnostic tools for U.S. healthcare systems, with Anumana as its inaugural partner. The marketplace features Anumana's FDA-cleared ECG-AI LEF algorithm, which analyzes standard 12-lead ECGs to identify reduced ejection fraction—a key indicator of heart failure—with the platform designed to reduce operational costs and improve workflow efficiency for healthcare organizations. This partnership positions both companies at the forefront of AI-enabled cardiac diagnostics while establishing a scalable model for future innovations in cardiovascular care.